Apollomics raises; Pear Therapeutics raises $64M; Lilly to acquire Loxo

Apollomics raises USD 100 Million for funding of transpacific cancer R&D plan

Apollomics has raised USD 100 million for funding an oncology clinical trial program. The series B round sets Apollomics to progress its c-Met inhibitor and pipeline of other clinical-phase assets. OrbiMed Asia-backed Apollomics has developed a pipeline of small molecules and monoclonal antibodies.  Apollomics has raised USD 100 million in a series B.

Pear Therapeutics raises USD 64 Million

San Francisco based Pear Therapeutics has raised USD 64 million for its prescription software to treat opioid disorder. The reSET-O prescription digital therapeutic for opioid use disorder consists of a 12-week cognitive behavioral therapy program intended to be used alongside outpatient treatment.

Eli Lilly to acquire Loxo Oncology for USD 8 Billion

The Stamford, Connecticut-based biopharma, Eli Lilly will acquire Loxo Oncology for USD 8 billion. Loxo quickly flourished in value since going public from USD 200 million to this USD 8 billion agreement. The biopharma got its first U.S. approval for its cancer drug Vitrakvi that was developed with its partner Bayer.